DOP2010000274A - Cristal de compuestos de bencimidazol - Google Patents

Cristal de compuestos de bencimidazol

Info

Publication number
DOP2010000274A
DOP2010000274A DO2010000274A DO2010000274A DOP2010000274A DO P2010000274 A DOP2010000274 A DO P2010000274A DO 2010000274 A DO2010000274 A DO 2010000274A DO 2010000274 A DO2010000274 A DO 2010000274A DO P2010000274 A DOP2010000274 A DO P2010000274A
Authority
DO
Dominican Republic
Prior art keywords
bencimidazol
composite crystal
crystal
3emethyl
trifluoroethoxy
Prior art date
Application number
DO2010000274A
Other languages
English (en)
Inventor
Hideo Hashimoto
Tadashi Urai
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40577894&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2010000274(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of DOP2010000274A publication Critical patent/DOP2010000274A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se provee un cristal de (R)e2e[[[3emetil--4e(2,2,2e trifluoroetoxi)e2epiridinil]metil]sulfinil]e1H-- bencimidazol que muestra un patrón de análisis de difracción de rayos X de polvo con picos característicos en espacios interplanos (d) de 1O,06±O,2, 8,70±O,2, 6,57±O,2, 5,59±O,2 y 4,OO±O,2 Angstroms. La presente invención provee un fármaco antiúlcera estable superior en la absorbabilidad.
DO2010000274A 2008-03-10 2010-09-10 Cristal de compuestos de bencimidazol DOP2010000274A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2008059342 2008-03-10

Publications (1)

Publication Number Publication Date
DOP2010000274A true DOP2010000274A (es) 2010-09-30

Family

ID=40577894

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2010000274A DOP2010000274A (es) 2008-03-10 2010-09-10 Cristal de compuestos de bencimidazol

Country Status (30)

Country Link
US (1) US8222422B2 (es)
EP (1) EP2262790B1 (es)
JP (3) JP2011513202A (es)
KR (1) KR20100123758A (es)
CN (1) CN102026994B (es)
AR (1) AR070972A1 (es)
AU (1) AU2009224247B2 (es)
BR (1) BRPI0909651A2 (es)
CA (1) CA2671369C (es)
CL (1) CL2009000547A1 (es)
CO (1) CO6300956A2 (es)
CR (1) CR11707A (es)
DO (1) DOP2010000274A (es)
EA (1) EA017064B1 (es)
EC (1) ECSP10010531A (es)
ES (1) ES2638463T3 (es)
GE (1) GEP20125649B (es)
IL (1) IL207867A0 (es)
LT (1) LT2262790T (es)
MA (1) MA32215B1 (es)
MX (1) MX2010009641A (es)
MY (1) MY150833A (es)
NZ (1) NZ588379A (es)
PE (1) PE20091680A1 (es)
PT (1) PT2262790T (es)
TW (1) TWI447110B (es)
UA (1) UA103189C2 (es)
UY (1) UY31695A (es)
WO (1) WO2009113696A1 (es)
ZA (1) ZA201006754B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011004387A2 (en) 2009-06-18 2011-01-13 Matrix Laboratories Ltd Process for the preparation of dexlansoprazole polymorphic forms
CN102108077B (zh) * 2009-12-23 2013-09-25 江苏豪森医药集团有限公司 制备右兰索拉唑的方法
EP2528912A1 (en) * 2010-01-29 2012-12-05 Ranbaxy Laboratories Limited Process for the preparation of crystalline forms of dexlansoprazole
CN104447695A (zh) * 2013-11-22 2015-03-25 广东东阳光药业有限公司 一种苯并咪唑化合物的水合物
US10512635B2 (en) 2015-06-08 2019-12-24 Cj Healthcare Corporation Uses of benzimidazole derivative for nocturnal acid breakthrough
IL266955B2 (en) * 2016-11-29 2023-09-01 Ptc Therapeutics Mp Inc Polymorphs of spiafatrin and its salts
CN106866631A (zh) * 2017-04-06 2017-06-20 山东裕欣药业有限公司 一种右旋兰索拉唑晶型及制备方法
CA3073957A1 (en) 2017-09-01 2019-03-07 Censa Pharmaceuticals Inc. Pharmaceutical compositions comprising sepiapterin and uses thereof
CN117843645A (zh) * 2018-05-25 2024-04-09 伊马拉公司 一种pde9抑制剂的一水合物和结晶形态
US11365170B2 (en) * 2018-07-13 2022-06-21 Kyowa Hakko Bio Co., Ltd. Non-solvate crystal of eucomic acid and method for producing same
CN113376273B (zh) * 2021-06-02 2023-03-17 国药集团精方（安徽）药业股份有限公司 一种清心莲子饮hplc特征图谱的检测方法及该特征图谱的应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
DK171989B1 (da) 1987-08-04 1997-09-08 Takeda Chemical Industries Ltd Fremgangsmåde til fremstilling af 2-(2-pyridylmethylsulfinyl)-benzimidazoler
DE4035455A1 (de) 1990-11-08 1992-05-14 Byk Gulden Lomberg Chem Fab Enantiomerentrennung
SE504459C2 (sv) 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
GB9423968D0 (en) 1994-11-28 1995-01-11 Astra Ab Resolution
HRP960232A2 (en) 1995-07-03 1998-02-28 Astra Ab A process for the optical purification of compounds
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
TW385306B (en) * 1996-11-14 2000-03-21 Takeda Chemical Industries Ltd Method for producing crystals of benzimidazole derivatives
EP0941102A1 (en) 1996-11-22 1999-09-15 The Procter & Gamble Company Compositions for the treatment of gastrointestinal disorders containing bismuth and nsaid
SE510666C2 (sv) 1996-12-20 1999-06-14 Astra Ab Nya Kristallmodifikationer
DE59801792D1 (de) * 1997-08-08 2001-11-22 Aventis Pharma Gmbh Kristallform von N-(4-Trifluormethylphenyl)-5-methylisoxazol-4-carbonsäureamid
JP2002501896A (ja) 1998-01-30 2002-01-22 セプラコール， インク． Ｓ−ランソプラゾール組成物及び方法
CA2320963A1 (en) 1998-01-30 1999-08-05 Sepracor, Inc. R-lansoprazole compositions and methods
EP1075267A2 (en) 1998-05-06 2001-02-14 Kobenhavns Universitet Treatment of celiac disease
JP3283252B2 (ja) * 1999-06-17 2002-05-20 武田薬品工業株式会社 ベンズイミダゾール化合物の結晶
TWI275587B (en) * 1999-06-17 2007-03-11 Takeda Chemical Industries Ltd A crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
JP4327424B2 (ja) * 2000-05-15 2009-09-09 武田薬品工業株式会社 結晶の製造法
ES2293988T3 (es) 2000-05-15 2008-04-01 Takeda Pharmaceutical Company Limited Procedimiento para producir un cristal.
JP3374314B2 (ja) * 2000-05-15 2003-02-04 武田薬品工業株式会社 結晶の製造法
PL399787A1 (pl) 2000-12-01 2012-11-05 Takeda Pharmaceutical Company Ltd. Krysztaly (R)- lub (S)-2-[[[3-metylo-4-(2,2,2-trifluoroetoksy)-2-pirydynylo]metylo]sulfinylo]-1H-benzimidazolu, kompozycja farmaceutyczna zawierajaca te krysztaly i ich zastosowanie
JP4160293B2 (ja) * 2000-12-01 2008-10-01 武田薬品工業株式会社 結晶の製造法
US8697094B2 (en) 2002-10-16 2014-04-15 Takeda Pharmaceutical Company Limited Stable solid preparations
JP4749660B2 (ja) * 2002-10-16 2011-08-17 武田薬品工業株式会社 安定な固形製剤
WO2009088857A1 (en) 2007-12-31 2009-07-16 Takeda Pharmaceutical Company Limited Crystalline solvated forms of (r) -2- [ [ [3-methyl-4- (2, 2, 2-trifluoroethoxy) -2-pyridinyl] methyl] sulfinyl] -1h-benz imidazole

Also Published As

Publication number Publication date
UA103189C2 (ru) 2013-09-25
TW200938531A (en) 2009-09-16
IL207867A0 (en) 2010-12-30
CR11707A (es) 2010-11-04
CA2671369C (en) 2011-05-10
TWI447110B (zh) 2014-08-01
LT2262790T (lt) 2017-08-25
JP2015163623A (ja) 2015-09-10
ECSP10010531A (es) 2010-11-30
BRPI0909651A2 (pt) 2015-09-22
EA201071053A1 (ru) 2011-04-29
AU2009224247A1 (en) 2009-09-17
MY150833A (en) 2014-02-28
JP2011513202A (ja) 2011-04-28
WO2009113696A1 (en) 2009-09-17
MX2010009641A (es) 2010-09-22
PE20091680A1 (es) 2009-11-16
EP2262790A1 (en) 2010-12-22
CA2671369A1 (en) 2009-09-10
CN102026994A (zh) 2011-04-20
KR20100123758A (ko) 2010-11-24
AR070972A1 (es) 2010-05-19
NZ588379A (en) 2012-07-27
US8222422B2 (en) 2012-07-17
CO6300956A2 (es) 2011-07-21
ES2638463T3 (es) 2017-10-20
AU2009224247B2 (en) 2013-12-12
AU2009224247A2 (en) 2010-10-28
UY31695A (es) 2009-11-10
EA017064B1 (ru) 2012-09-28
CN102026994B (zh) 2014-05-07
JP2014015477A (ja) 2014-01-30
ZA201006754B (en) 2011-11-30
CL2009000547A1 (es) 2010-05-07
PT2262790T (pt) 2017-07-18
EP2262790B1 (en) 2017-06-07
MA32215B1 (fr) 2011-04-01
US20110046183A1 (en) 2011-02-24
GEP20125649B (en) 2012-09-25

Similar Documents

Publication Publication Date Title
DOP2010000274A (es) Cristal de compuestos de bencimidazol
DE602007006525D1 (de) 2-aryl-6-phenylimidazoä1,2-aüpyridin-derivate, ihre herstellung und therapeutische verwendung
EP2143713A4 (en) NEW PYRROLINONE DERIVATIVE AND MEDICAL COMPOSITION CONTAINING THIS
BRPI0917315A2 (pt) anticorpo, composicao farmaceutico, e, uso de uma composicao farmaceutica
MY161550A (en) Extended release oral acetaminophen/tramadol dosage form
IL195820A0 (en) Derivatives of ureas of piperidine or pyrrolidine, their preparation and their therapeutical use
MX2009006235A (es) Composiciones farmaceuticas y sus metodos de uso.
BR112012029617A2 (pt) "composição, método para produzir um filme de auto-suporte, filme de auto-suporte, objeto de múltiplas camadas, método para a produção de um objeto de múltiplas camadas e uso de uma comnposição"
BRPI0820391A2 (pt) Composto, composição e métodos de modulação da expressão do fator 7
EP2219616A4 (en) TAXAN DERIVATIVES LYOPHILIZED PHARMACEUTICAL COMPOSITION WITH IMPROVED STABILITY AND MANUFACTURING METHOD THEREFOR
EP2336109A4 (en) NOVEL PYRROLINONE DERIVATIVE AND DRUG COMPOSITION CONTAINING THE SAME
IL192944A0 (en) THE USE OF AN ANTI-EpCAM ANTIBODY FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION
AU2006256369A8 (en) Novel salts of conjugated psychotropic drugs and processes of preparing same
EP2246338A4 (en) NEW CATÉCHOL DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, USE OF THE CATÉCHOL DERIVATIVE, AND USE OF THE PHARMACEUTICAL COMPOSITION
MX2010001574A (es) Ligandos del receptor cannabinoide.
ATE489944T1 (de) Pharmazeutische feste zubereitung mit benzazepinen und herstellungsverfahren dafür
DE602008000104D1 (de) Neue trizyklische Derivate, ihr Herstellungsverfahren und pharmazeutische Zusammensetzungen, die sie enthalten
DE602008005137D1 (de) Chinolonverbindung und pharmazeutische zusammensetzung
ATE548349T1 (de) In stellung 3 disubstituierte indol-2-on- pyridinderivate, ihre herstellung sowie ihre therapeutische anwendung
ATE540023T1 (de) Neuartige 3-aminoalkyl-1,3-dihydro-2h-indol-2-on- derivate, ihre herstellung und therapeutische verwendung
BRPI0815531A2 (pt) "compostos, composição farmacêutica, composição cosmética, uso cosmético de uma composição e uso de um composto"
ATE520654T1 (de) Polypyrrol-derivate, ihre herstellung und ihre therapeutische verwendung
DE602007012699D1 (de) Aryl- und heteroaryl-ethyl-acylguanidinderivate, ihre herstellung und ihre therapeutische anwendung
IL200069A0 (en) Atorvastatin strontium salts, pharmaceutical composition comprising the same and methods of producing the same
ATE537172T1 (de) Triazolopyridazine als par1-inhibitoren, ihre herstellung und verwendung als arzneimittel